The present invention concerns a pharmaceutical composition formed by the synergistic combination of a selective serotonin reuptake inhibitor, such as the active principle: Paroxetine hydrochloride hemihydrate and an agent belonging to the triazolobenzodiazepine group, such as the active principle: Alprazolam, as well as pharmaceutically acceptable excipients； which are formulated in a single dosing unit to be administered by oral means, said unit being prescribed for the treatment and control of major depressive episodes, symptoms of Obsessive-Compulsive disorder (OCD), panic attacks with or without agoraphobia, generalized anxiety disorders, social phobia and post-traumatic stress disorder.
